Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artivion, Inc. stock logo
AORT
Artivion
$36.17
+4.1%
$36.50
$28.07
$48.25
$1.76B1.41398,803 shs150,522 shs
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$16.10
+0.6%
$16.57
$10.99
$18.92
$5.74B0.59418,663 shs56,318 shs
Envista Holdings Corporation stock logo
NVST
Envista
$25.50
-5.8%
$26.63
$16.41
$30.42
$4.14B0.922.74 million shs3.71 million shs
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€18.10
-4.7%
€15.11
€12.89
€28.00
€5.45B0.75662,719 shs121,665 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artivion, Inc. stock logo
AORT
Artivion
-3.38%+0.34%+3.62%-12.05%+26.51%
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
+0.16%+4.05%-2.07%-2.34%+46.93%
Envista Holdings Corporation stock logo
NVST
Envista
+3.63%+4.76%+5.21%+9.40%+65.68%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
+4.69%+16.99%+38.59%+34.45%-10.39%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artivion, Inc. stock logo
AORT
Artivion
$36.17
+4.1%
$36.50
$28.07
$48.25
$1.76B1.41398,803 shs150,522 shs
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$16.10
+0.6%
$16.57
$10.99
$18.92
$5.74B0.59418,663 shs56,318 shs
Envista Holdings Corporation stock logo
NVST
Envista
$25.50
-5.8%
$26.63
$16.41
$30.42
$4.14B0.922.74 million shs3.71 million shs
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€18.10
-4.7%
€15.11
€12.89
€28.00
€5.45B0.75662,719 shs121,665 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artivion, Inc. stock logo
AORT
Artivion
-3.38%+0.34%+3.62%-12.05%+26.51%
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
+0.16%+4.05%-2.07%-2.34%+46.93%
Envista Holdings Corporation stock logo
NVST
Envista
+3.63%+4.76%+5.21%+9.40%+65.68%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
+4.69%+16.99%+38.59%+34.45%-10.39%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artivion, Inc. stock logo
AORT
Artivion
2.88
Moderate Buy$51.0041.00% Upside
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.21
Hold$18.0812.32% Upside
Envista Holdings Corporation stock logo
NVST
Envista
2.40
Hold$28.3311.11% Upside
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
2.40
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest AORT, BLCO, STVN, and NVST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2026
Envista Holdings Corporation stock logo
NVST
Envista
Reiterated RatingOutperform$33.00
5/7/2026
Envista Holdings Corporation stock logo
NVST
Envista
Boost Price TargetOutperform$30.00 ➝ $31.00
4/30/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Set Price Target$16.00
4/24/2026
Envista Holdings Corporation stock logo
NVST
Envista
Boost Price TargetEqual Weight$19.00 ➝ $21.00
4/20/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Reiterated RatingSell (D-)
4/20/2026
Artivion, Inc. stock logo
AORT
Artivion
Reiterated RatingBuy
4/15/2026
Envista Holdings Corporation stock logo
NVST
Envista
Initiated CoverageNeutral$29.00
4/15/2026
Envista Holdings Corporation stock logo
NVST
Envista
Initiated CoverageHold$29.00
4/10/2026
Artivion, Inc. stock logo
AORT
Artivion
UpgradeNeutralBuy$42.00
4/8/2026
Envista Holdings Corporation stock logo
NVST
Envista
Set Price Target$30.00
4/7/2026
Artivion, Inc. stock logo
AORT
Artivion
Reiterated RatingBuy$58.00
(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artivion, Inc. stock logo
AORT
Artivion
$441.33M3.97$1.11 per share32.59$9.46 per share3.82
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$5.10B1.12$1.68 per share9.59$18.10 per share0.89
Envista Holdings Corporation stock logo
NVST
Envista
$2.72B1.53$2.11 per share12.06$18.89 per share1.35
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€1.19B4.62€0.88 per share20.64€5.55 per share3.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artivion, Inc. stock logo
AORT
Artivion
$9.77M$0.20181.3237.68N/A2.21%7.43%3.53%5/7/2026 (Estimated)
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$360M-$0.62N/A14.910.49-4.21%3.60%1.69%N/A
Envista Holdings Corporation stock logo
NVST
Envista
$47M$0.2890.8116.451.791.73%6.54%3.60%N/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€158.21M€0.5831.0021.551.6311.83%10.44%6.22%5/7/2026 (Confirmed)

Latest AORT, BLCO, STVN, and NVST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Artivion, Inc. stock logo
AORT
Artivion
$0.06N/AN/AN/A$115.69 millionN/A
5/7/2026Q1 2026
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€0.12€0.11-€0.01€0.12N/AN/A
5/6/2026Q1 2026
Envista Holdings Corporation stock logo
NVST
Envista
$0.31$0.36+$0.05$0.23$680.04 million$705.50 million
4/29/2026Q1 2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.06$0.08+$0.02-$0.20$1.22 billion$1.24 billion
2/18/2026Q4 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.35$0.32-$0.03-$0.16$1.38 billion$1.41 billion
2/14/2026Q4 2025
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/A€0.18N/A€0.17N/A€346.50 million
2/12/2026Q4 2025
Artivion, Inc. stock logo
AORT
Artivion
$0.14$0.17+$0.03$0.05$116.42 million$118.30 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Artivion, Inc. stock logo
AORT
Artivion
N/AN/AN/AN/AN/A
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Envista Holdings Corporation stock logo
NVST
Envista
N/AN/AN/AN/AN/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/AN/AN/AN/A1 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artivion, Inc. stock logo
AORT
Artivion
0.49
3.53
2.62
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.78
1.53
0.99
Envista Holdings Corporation stock logo
NVST
Envista
0.47
2.38
2.04
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.23
1.76
1.26

Institutional Ownership

CompanyInstitutional Ownership
Artivion, Inc. stock logo
AORT
Artivion
86.37%
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
Envista Holdings Corporation stock logo
NVST
Envista
N/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/A

Insider Ownership

CompanyInsider Ownership
Artivion, Inc. stock logo
AORT
Artivion
6.30%
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
1.45%
Envista Holdings Corporation stock logo
NVST
Envista
0.99%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artivion, Inc. stock logo
AORT
Artivion
1,80048.50 million45.44 millionOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,000356.40 million351.23 millionOptionable
Envista Holdings Corporation stock logo
NVST
Envista
12,000162.98 million161.37 millionOptionable
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
6,010302.84 million300.72 millionOptionable

Recent News About These Companies

Here’s Why Stevanato Group Spa (STVN) Declined in Q1
Stevanato Group SpA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Artivion stock logo

Artivion NYSE:AORT

$36.17 +1.44 (+4.14%)
As of 11:14 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$16.10 +0.10 (+0.63%)
As of 11:14 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Envista stock logo

Envista NYSE:NVST

$25.50 -1.57 (-5.80%)
As of 11:14 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

Stevanato Group stock logo

Stevanato Group NYSE:STVN

€18.10 -0.90 (-4.74%)
As of 11:13 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.